Beijing University of Technology

University of South Australia

Central Adelaide Local Health Network Inc.

Everbrilliant Pharma Pty Ltd

Bing Wang

Bernard Luke Flynn

Carmen Vittoria Scullino

Peter Scammells

Stuart Maxwell Pitson

Jamie Simpson

Luigi Aurelio

David Chalmers

Melissa Rose Pitman

Henry Krum

Natalie Vinh

The present invention relates to certain novel substituted thiophene compounds and the finding that they display useful efficacy in the inhibition of the p38&#x3b1; MAPK enzyme. This provides for use of the compounds in various treatment methodologies related to MAPK inhibition, including the treatment of inflammation.

MAPK inhibitors

The present disclosure relates generally, but not exclusively, to compounds and their use as enzyme interacting agents, in particular, agents which interact with one or more enzymes in the sphingolipid biosynthesis pathway. The disclosure further relates to the use of such compounds as research tools, use in therapy, to compositions and agents comprising said compounds, and to methods of treatment using said compounds.

Enzyme interacting agents

Growing community of inventors

Camberwell, Australia

Bing Wang